Updated:
Biofrontera
Hermann Luebbert chairs Biofrontera, a commercial-stage biopharma focused on FDA-approved photodynamic therapy for dermatology.
Biofrontera
Biofrontera Inc. operates as the US-focused commercial arm of Biofrontera AG, the German parent that developed the Ameluz (aminolevulinic acid hydrochloride) topical gel and the BF-RhodoLED photodynamic therapy lamp. Hermann Luebbert leads the US entity as Chairman and CEO, driving a specialty pharmaceutical model that markets directly to US dermatologists. The company does not function as a fund or family office — it is an operating business that invests its revenue into product sales infrastructure and clinical trials. Biofrontera's core strategy revolves around prescription dermatology, specifically photodynamic therapy (PDT) for the field-directed treatment of actinic keratosis on the face and scalp. Its platform includes Ameluz, the BF-RhodoLED lamp series, and the recently acquired Xepi (ozenoxacin) cream for impetigo. Beyond the US, the German parent controls commercialization across Europe, and the firms have executed supply and distribution agreements for markets including Israel. The company finances its operations through a combination of product revenue, licensing milestones, and equity-linked instruments, such as the January 2021 tolerance waiver and subsequent public offering of common stock. February 2025: Biofrontera Inc. appointed Sean P. McGowan as Chief Financial Officer, succeeding Fred Leffler, signaling a continued refinement of the US management team as the firm works to expand its dermatology product portfolio and market penetration in the PDT segment. Structurally, Biofrontera occupies an unusual position as a US-listed vehicle (NASDAQ: BFRI) that is majority-controlled but operationally distinct from its German parent, Biofrontera AG. This dual-listed, cross-Atlantic architecture creates a specific investment profile: a US commercial business with a pipeline tied to European R&D, accessing US public markets while navigating the governance and capital-allocation tensions inherent in a controlled-company structure.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Woburn
Corporate office
Woburn, MA, United States
Principals
Hermann Luebbert
Chairman and CEO
Sector focus
Frequently asked questions
Is Biofrontera Inc. a family office or an operating business?
Biofrontera Inc. is an operating pharmaceutical company, not a family office or investment vehicle. It is the US-listed subsidiary of Biofrontera AG, responsible for commercializing dermatology products such as Ameluz and the BF-RhodoLED lamp system directly to US physicians. The firm generates revenue from product sales and reinvests in its commercial infrastructure and clinical programs.
What is the relationship between Biofrontera Inc. and Biofrontera AG?
Biofrontera Inc. (NASDAQ: BFRI) is the US commercial subsidiary of Biofrontera AG, a German pharmaceutical company. The US entity holds the exclusive license for North American commercialization of Ameluz and the BF-RhodoLED photodynamic therapy platform. Biofrontera AG retains a controlling equity stake in the US entity and conducts the underlying R&D and manufacturing operations.
Does Biofrontera Inc. make external investments in other biotech firms?
No. Biofrontera Inc. does not operate as a corporate venture capital arm or make passive investments in external biotech companies. Its capital allocation is focused entirely on the commercialization of its own dermatology products, the acquisition of approved or late-stage assets like Xepi, and the funding of clinical trials to expand the labeled indications for its existing PDT platform.
What is Biofrontera's current product portfolio?
The portfolio is built around photodynamic therapy for dermatology. The lead product is Ameluz, a topical gel used in combination with the BF-RhodoLED lamp to treat actinic keratosis. In 2022, the company acquired the US rights to Xepi (ozenoxacin) cream, a topical antibiotic for impetigo, diversifying its prescription dermatology offering beyond PDT.
Who runs the US investment and commercial strategy?
Hermann Luebbert serves as Chairman and CEO of Biofrontera Inc., overseeing the US commercial strategy. He is supported by a dedicated US management team based in Woburn, Massachusetts. As of February 2025, Sean P. McGowan holds the CFO role, responsible for the company's capital markets activities and financial operations.
Why is Biofrontera Inc. considered an unusual structure for a pharmaceutical company?
The firm has a dual-listed structure where a German parent company controls the US operating subsidiary that is separately listed on NASDAQ. This creates a different governance profile than a standalone US biotech and subjects the US entity to the capital allocation and strategic decisions of its European parent, while still requiring it to independently access US public markets for financing.
What therapeutic areas does Biofrontera explicitly avoid?
Biofrontera is narrowly focused on prescription dermatology and does not pursue oncology, systemic autoimmune diseases, or rare genetic disorders. The company's stated pipeline is built around expanding the labeled indications for its existing photodynamic therapy platform and acquiring approved dermatology assets, rather than funding early-stage discovery programs outside of skin-related conditions.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: